Indeed, our preclinical data on dual targeting of MALT1 and BTK using combinations of the respective inhibitors demonstrates that this treatment strategy promotes potent anti-MCL activity in MCL cells with resistance to BTKis. The gene discussed is MALT1; the disease is mantle cell lymphoma.